We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

191 hedge funds and large institutions have $690M invested in Meridian Bioscience Inc in 2018 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 56 increasing their positions, 66 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,215% more call options, than puts

Call options by funds: $2.25M | Put options by funds: $171K

85% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 20

17% more capital invested

Capital invested by funds: $592M → $690M (+$97.9M)

8% more funds holding

Funds holding: 177191 (+14)

15% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 66

Holders
191
Holders Change
+14
Holders Change %
+7.91%
% of All Funds
4.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
37
Increased
56
Reduced
66
Closed
20
Calls
$2.25M
Puts
$171K
Net Calls
+$2.08M
Net Calls Change
+$936K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$109M +$1.14M +67,044 +1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$76.6M +$1.14M +66,580 +2%
BCM
3
Brown Capital Management
Maryland
$63.5M -$107K -6,254 -0.2%
Renaissance Technologies
4
Renaissance Technologies
New York
$50.2M +$1.57M +92,140 +3%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$33M +$254K +14,871 +0.8%
State Street
6
State Street
Massachusetts
$23.9M -$369K -21,636 -2%
Norges Bank
7
Norges Bank
Norway
$22.1M
SFM
8
Systematic Financial Management
New Jersey
$20M +$179K +10,473 +0.9%
Invesco
9
Invesco
Georgia
$18.9M +$7.05M +413,234 +61%
PP
10
Prudential plc
United Kingdom
$18.1M
Geode Capital Management
11
Geode Capital Management
Massachusetts
$14.2M -$191K -11,220 -1%
VNIM
12
Vaughan Nelson Investment Management
Texas
$13.3M +$13.1M +765,940 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$12.1M -$2.17M -127,082 -15%
Morgan Stanley
14
Morgan Stanley
New York
$10.8M +$1.72M +100,865 +19%
Northern Trust
15
Northern Trust
Illinois
$9.74M -$290K -17,011 -3%
Charles Schwab
16
Charles Schwab
California
$7.97M +$280K +16,411 +4%
Ameriprise
17
Ameriprise
Minnesota
$6.86M -$224K -13,129 -3%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$6.67M +$686K +40,236 +12%
Wells Fargo
19
Wells Fargo
California
$6.55M -$9.74K -571 -0.2%
Principal Financial Group
20
Principal Financial Group
Iowa
$6.24M -$1.65K -97 -0%
PPA
21
Parametric Portfolio Associates
Washington
$6.13M -$1.55M -90,630 -20%
JP Morgan Chase
22
JP Morgan Chase
New York
$5.21M -$4.87M -285,570 -49%
MAM
23
Martingale Asset Management
Massachusetts
$5.1M +$351K +20,600 +8%
Arrowstreet Capital
24
Arrowstreet Capital
Massachusetts
$5.05M +$1.96M +114,754 +65%
SBH
25
Segall Bryant & Hamill
Illinois
$4.33M -$475K -27,870 -10%

VIVO Hedge Fund Activity: Q4 2018 in Review

191 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2018, worth a combined $690M — up 17% from $592M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new VIVO positions and 20 closed out — a net gain of 17 holders — while 56 added to existing stakes and 66 trimmed.

The largest buyer was Vaughan Nelson Investment Management, opening a new position worth an estimated $13.1M. The largest seller was AJO LP, exiting entirely with an estimated $6.24M sold.

  • 191 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2018, up from 177 in Q3 2018.
  • Funds reported $690M of Meridian Bioscience Inc stock for Q4 2018, up 17% quarter-over-quarter.
  • 37 funds opened new Meridian Bioscience Inc positions in Q4 2018 and 20 closed out, a net change of +17 holders.
  • The largest Meridian Bioscience Inc buyer in Q4 2018 was Vaughan Nelson Investment Management, an estimated $13.1M added.
  • The largest Meridian Bioscience Inc seller in Q4 2018 was AJO LP, an estimated $6.24M sold.

Based on aggregated 13F filings for Q4 2018.